February 11, 2022 07:12 AM EST
FDA+

FDA re­jects cit­i­zen pe­ti­tion claim­ing Cas­sa­va ma­nip­u­lat­ed da­ta, but the biotech's woes are not over

Max Gelman

Senior Editor

Un­der fire from all fronts over al­le­ga­tions of da­ta ma­nip­u­la­tion, Cas­sa­va Sci­ences picked up a small win Thurs­day, but isn’t out of the woods yet …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times